Op-Ed: The Debate Underpinning FDA’s Approval of a New Alzheimer’s Drug
The controversy over the Food and Drug Administration’s use of its accelerated approval pathway to make a new treatment for Alzheimer’s disease available raises broader, fundamental issues about the purpose and management of our nation’s health care system. Those of us who rely on this system believe that its purpose is twofold: mitigate our risk